Cas:1212008-99-5 [1,3-Bis(2,6-diisopropylphenyl)-2-imidazolidinylidene](dichloro){ 2-isopropoxy-5-[(trifluoroacetyl)amino]benzylidene}ruthenium manufacturer & supplier

Chemical Name:[1,3-Bis(2,6-diisopropylphenyl)-2-imidazolidinylidene](dichloro){ 2-isopropoxy-5-[(trifluoroacetyl)amino]benzylidene}ruthenium

CAS.NO:1212008-99-5

Synonyms:[1,3-Bis(2,6-diisopropylphenyl)-2-imidazolidinylidene](dichloro){2-isopropoxy-5-[(trifluoroacetyl)amino]benzylidene}ruthenium;Ruthenium, [1,3-bis[2,6-bis(1-methylethyl)phenyl]-2-imidazolidinylidene]dichloro[[2-(1-methylethoxy)-5-[(2,2,2-trifluoroacetyl)amino]phenyl]methylene]-

Molecular Formula:C₃₉H₅₀Cl₂F₃N₃O₂Ru

Molecular Weight:821.804

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:79.52000

Exact Mass:821.227600

LogP:8.13730

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like [1,3-Bis(2,6-diisopropylphenyl)-2-imidazolidinylidene](dichloro){2-isopropoxy-5-[(trifluoroacetyl)amino]benzylidene}ruthenium chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Ruthenium, [1,3-bis[2,6-bis(1-methylethyl)phenyl]-2-imidazolidinylidene]dichloro[[2-(1-methylethoxy)-5-[(2,2,2-trifluoroacetyl)amino]phenyl]methylene]- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Ruthenium, [1,3-bis[2,6-bis(1-methylethyl)phenyl]-2-imidazolidinylidene]dichloro[[2-(1-methylethoxy)-5-[(2,2,2-trifluoroacetyl)amino]phenyl]methylene]- Use and application,Ruthenium, [1,3-bis[2,6-bis(1-methylethyl)phenyl]-2-imidazolidinylidene]dichloro[[2-(1-methylethoxy)-5-[(2,2,2-trifluoroacetyl)amino]phenyl]methylene]- technical grade,usp/ep/jp grade.

Related News: Walmsley’s background in consumer health—and lack of prior experience in pharma—has reportedly been targeted by Elliott in the investment firm’s secret push for a new boss at GSK. (1,3-dimethyl-1,3-dihydro-2H-imidazol-2-ylidene)(1-(8-iodooctyl)-3-methyl-1,3-dihydro-2H-imidazol-2-ylidene)palladium(VI) iodide manufacturers The inhaled version was also found to trigger neutralising antibodies and T cell responses after one dose. Thiophene, 2,3-dihydro-5-methyl-3-(phenylseleno)-, 1,1-dioxide suppliers AstraZeneca acquired global rights to anifrolumab through an exclusive license and collaboration agreement with Medarex, Inc. in 2004. Medarex was acquired by Bristol-Myers Squibb in 2009. 2-Methyl-6-propionyl-cyclohexanone vendor & factory.